Prostate cancer (Prostatic Neoplasms, PCa in English) is the most common malignant tumor of the male reproductive system. The incidence rate in China has increased significantly and is on the rise. It is expected to be close to the incidence rate in Western developed countries within a few years. Endocrine therapy, that is, anti-androgen therapy is the first choice for prostate cancer, and the effect is relatively ideal. However, resistance to endocrine therapy is one of the main reasons for treatment failure. A large number of clinical data prove that ACTL targeted cellular immunotherapy can not only directly kill prostate cancer cells, but also delay or prevent the emergence of resistance to endocrine therapy and achieve satisfactory results. So what diagnostic tests are needed for prostate cancer before receiving ACTL targeted cellular immunotherapy?
 
1. Blood test
1. Blood prostate specific antigen (PSA) examination
2. Routine blood test for liver function, kidney function, hepatitis B, hepatitis C, AIDS and other infectious diseases

Two, imaging examination
Including CT, MRI and magnetic, PET-CT, PET-CT is recommended for patients with obvious metastases.
 
3. Assessment report of the overall physical condition
Hospital inpatient medical records

4. Previous and current treatment information